Intellectual Property

Auxogyn’s Intellectual Property Reflects our Commitment to Innovation

Auxogyn is committed to developing innovative technologies that advance the field of reproductive health and make a difference in the lives of families. Auxogyn invests significant resources to provide the best possible technologies for our customers and their patients. Our patents and other intellectual property are one aspect of that commitment.

Our initial intellectual property is licensed from Stanford University, and reflects ground-breaking work in understanding human embryo development described in part in a publication titled ’Non-invasive imaging of human embryos before embryonic genome activation predicts development to the blastocyst stage, published in Nature Biotechnology, 2010.

Our first issued patent (United States Patent Number 7,963,906 (’906 Patent)) is licensed from Stanford University and covers predictive parameters for the assessment of embryo viability during in vitro fertilization (IVF) procedures used in the Eeva™ System. Additional U.S. patents have issued (United States Patent Numbers 8,323,177, 8,337,387 and 8,721,521) that are also licensed exclusively to Auxogyn by Stanford University and cover various methods of determining the development potential of a human embryo in vitro using time lapse imaging and key cellular timing parameters. Corresponding patents have either registered or have been granted in a number of foreign countries.

Auxogyn also has a broad portfolio of patents and patent applications worldwide related to reproductive health and Auxogyn’s technology (including additional patents that have been allowed).

Auxogyn respects the intellectual property of others, and expects others to respect our intellectual property. Auxogyn takes pride in our innovative history and looks forward to providing many new, exciting technologies in the future. Please contact us at if you have any questions regarding Auxogyn’s intellectual property.